What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2023-08-14 compared with 2023-05-12 · 296 added, 278 removed, 26 unchanged (96% of the section changed)

Management’s Discussion and Analysis of Financial

Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements

that relate to future events and expectations and, as such, constitute forward-looking statements, within the meaning of the Private Securities

Litigation Reform Act of 1995.

Certain statements, other than purely historical information, including estimates, projections, statements

relating to our strategies, outlook, business and financial prospects, business plans, objectives, and expected operating results, and

the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements

generally are identified by the words “believes,” “project,” “expects,” “anticipates,”

“estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,”

“will be,” “will continue,” “will likely result,” and similar expressions.

Forward-looking statements are based on current

expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the

forward-looking statements.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking

Quarterly Report on Form 10-Q contains statements that relate to future events and expectations and, as such, constitute forward-looking

statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Certain statements, other than purely historical

information, including estimates, projections, statements relating to our strategies, outlook, business and financial prospects, business

plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking

statements.” These forward-looking statements generally are identified by the words “believes,” “project,”

“expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,”

“may,” “will,” “would,” “will be,” “will continue,” “will likely result,”

and similar expressions.

Forward-looking

statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results

to differ materially from the forward-looking statements.

Forward-looking statements are not guarantees of future performance.

Although OptimizeRx believes that the

expectations reflected in any forward-looking statements are based on reasonable assumptions, these expectations may not be attained and

it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of

risks, uncertainties and changes in circumstances, many of which are beyond OptimizeRx’s control.

Forward-looking statements are subject to risks

and uncertainties.

Actual results could differ materially from those expressed in or implied by such forward-looking statements due to

a variety of factors, including:

OptimizeRx believes that the expectations reflected in any forward-looking statements are based on reasonable assumptions, these expectations

may not be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements

due to a variety of risks, uncertainties and changes in circumstances, many of which are beyond OptimizeRx’s control.

Forward-looking

statements are subject to risks and uncertainties.

Actual results could differ materially from those expressed in or implied by such

forward-looking statements due to a variety of factors, including:

seasonal trends in the pharmaceutical brand marketing industry;

the inability to support our technology

and scale our operations successfully, developing and implementing new and updated applications, features and services for our portals

may be more difficult and expensive and take longer than expected;

the inability to offer high-quality customer support for our portals;

inability to support our technology and scale our operations successfully, developing and implementing new and updated applications,

features and services for our portals may be more difficult and expensive and take longer than expected;

the inability to offer high-quality

customer support for our portals;

dependence on a concentrated group of customers;

inability to maintain contracts with electronic prescription platforms, agreements with

electronic prescription platforms and electronic health record systems being subject to audit;

inability to attract and retain customers;

inability to maintain contracts with electronic prescription

platforms, agreements with electronic prescription platforms and electronic health record systems being subject to audit;

attract and retain customers;

inability to comply with laws and regulations that affect the healthcare industry;

developments in the healthcare industry;

in the healthcare industry;

inability to manage growth;

inability to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully;

inability to identify suitable acquisition candidates, complete acquisitions

or integrate acquisitions successfully;

inability to attract and retain senior management and other key employees;

economic, political, regulatory and other risks arising from

our international operations;

economic, political,

regulatory and other risks arising from our international operations;

inability to protect our intellectual property;

cybersecurity incidents;

reduction in the performance, reliability

and availability of our network infrastructure;

increases in costs due to inflation and other adverse economic conditions;

customer demand due to macroeconomic factors;

lack of a consistent active trading market for our common stock;

and volatility in the market

price of our common stock.

The risks and uncertainties included here are

not exhaustive.

Further information concerning our business, including additional factors that could materially affect our financial results,

is included herein and in our other filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31,

reduction in the performance, reliability and availability of our network infrastructure;

increases in costs due to inflation and other

adverse economic conditions;

decreases in customer demand due to macroeconomic factors;

lack of a consistent active trading market for

our common stock;

and volatility in the market price of our common stock.

risks and uncertainties included here are not exhaustive.

Further information concerning our business, including additional factors that

could materially affect our financial results, is included herein and in our other filings with the SEC, including our Annual Report

on Form 10-K for the year ended December 31, 2022.

Moreover, we operate in a rapidly changing and competitive environment.

New risk factors emerge from time to time, and it is not

possible for management to predict all such risk factors.

Further, it is not possible to assess the effect

of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ

materially from those contained in any forward-looking statements.

Given these risks and uncertainties, investors should not place undue

reliance on forward-looking statements as a prediction of actual results.

In addition, we disclaim any obligation to update any forward-looking

statements to reflect events or circumstances that occur after the date of this report.

We are a digital health technology company enabling

care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the

patient care journey.

factors emerge from time to time, and it is not possible for management to predict all such risk factors.

it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors,

may cause actual results to differ materially from those contained in any forward-looking statements.

Given these risks and uncertainties,

investors should not place undue reliance on forward-looking statements as a prediction of actual results.

In addition, we disclaim any

obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.

are a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and

patients at critical junctures throughout the patient care journey.

Connecting over 60% of U.S.

healthcare providers and millions of their patients through an intelligent technology

platform embedded within a proprietary point-of-care network, OptimizeRx helps patients start and stay on their medications.

Historically, our revenue was generated primarily

through the facilitation of financial messages to health care providers via their EHR and ePrescribe systems using the OptimizeRx proprietary

network to solve the ever-increasing communication barriers between pharmaceutical representatives and healthcare providers that have

presented in the rapidly changing healthcare industry.

Over time, as the demand for communication of an increasing variety of different

health information between life science companies, providers, and patients continued to rise, our platform has expanded to encompass additional

solutions that enable healthcare providers to access information for patients at the point of care.

These solutions include brand messaging,

therapeutic support messaging, brand support, and innovative patient engagement services, all of which now make up a significant portion

of our total revenue.

We employ a “land and expand” strategy

focused on growing our existing client base and generating greater and more consistent revenues in part through the continued shift in

our business model toward enterprise level engagements, while also broadening our platform with innovative proprietary solutions such

as our TelaRep™ virtual communication solution and our artificial intelligence-powered real-world data solution which uses sophisticated

proprietary algorithms to derive additional revenue from our existing network.

In addition, we have continued to expand our team in preparation

for future growth aspirations, which may be supplemented with future acquisitions and other strategic collaborations and investments.

Our strategy for driving revenue growth is also expected to work in tandem with our efforts to increase margin and profitability using

the aforementioned recurring revenue models that have inherently higher margins.

Because the pharmaceutical industry is dominated

by large companies with multiple brands, our revenue is concentrated in a relatively small number of companies.

We have approximately

100 pharmaceutical companies as customers, and our revenues are concentrated in these customers.

Loss of one of more of our larger customers

could have a negative impact on our operating results.

In general, the pharmaceutical brand marketing

industry experiences seasonal trends that affect the vast majority of participants in the pharmaceutical digital marketing industry.

pharmaceutical companies allocate the largest portion of their brand marketing to the fourth quarter of the calendar year.

the first quarter tends to reflect lower activity levels and lower revenue, with gradual increases in the following quarters.

expect these seasonality trends to continue and our ability to effectively manage our resources in anticipation of these trends may affect

our operating results.

Impact of Macroeconomic Events

Unfavorable conditions in the economy may negatively

affect the growth of our business and our results of operations.

For example, macroeconomic events including the COVID-19 pandemic, rising

inflation and the U.S.

healthcare providers and millions of

their patients through an intelligent technology platform embedded within a proprietary point-of-care network, OptimizeRx helps patients

start and stay on their medications.

Historically,

our revenue was generated primarily through the facilitation of financial messages to health care providers via their EHR and ePrescribe

systems using the OptimizeRx proprietary network to solve the ever-increasing communication barriers between pharmaceutical representatives

and healthcare providers that have presented in the rapidly changing healthcare industry.

Over time, as the demand for communication

of an increasing variety of different health information between life science companies, providers, and patients continued to rise, our

platform has expanded to encompass additional solutions that enable healthcare providers to access information for patients at the point

These solutions include brand messaging, therapeutic support messaging, brand support, and innovative patient engagement services,

all of which now make up a significant portion of our total revenue.

We employ a “land and expand” strategy focused on growing

our existing client base and generating greater and more consistent revenues in part through the continued shift in our business model

toward enterprise level engagements, while also broadening our platform with innovative proprietary solutions such as our artificial intelligence-powered

real-world data solution which uses sophisticated proprietary algorithms to derive additional revenue from our existing network.

will continue to optimize our portfolio of solutions to align our resource deployment to the best market opportunities.

the pharmaceutical industry is dominated by large companies with multiple brands, our revenue is concentrated in a relatively small number

of companies.

We have approximately 100 pharmaceutical companies as customers, and our revenues are concentrated in these customers.

Loss of one of more of our larger customers could have a negative impact on our operating results.

general, the pharmaceutical brand marketing industry experiences seasonal trends that affect the vast majority of participants in the

pharmaceutical digital marketing industry.

Many pharmaceutical companies allocate the largest portion of their brand marketing to the

fourth quarter of the calendar year.

As a result, the first half of the year tends to reflect lower activity levels and lower revenue,

with gradual increases in the following quarters.

We generally expect these seasonality trends to continue and our ability to effectively

manage our resources in anticipation of these trends may affect our operating results.

of Macroeconomic Events

conditions in the economy may negatively affect the growth of our business and our results of operations.

For example, macroeconomic

events including the COVID-19 pandemic, rising inflation and the U.S.

Federal Reserve raising interest rates have led to economic uncertainty.

In addition, high levels of employee turnover

across the pharmaceutical industry as well as a fewer number of U.S.

drug approvals could create additional uncertainty within our target

customer markets.

Historically, during periods of economic uncertainty and downturns, businesses may slow spending, which may impact our

business and our customers’ businesses.

Adverse changes in demand could impact our business, collection of accounts receivable and

our expected cash flow generation, which may adversely impact our financial condition and results of operations.

Key Performance Indicators

We monitor the following key performance indicators

to help us evaluate our business, measure our performance, identify trends affecting our business and make strategic decisions.

updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s

most updated list of “The top 20 pharma companies by 2022 revenue”.

We previously used “The top 20 pharma companies by

2020 revenue”.

As a result of this change, prior periods have been restated for comparative purposes.

Average revenue per top 20 pharmaceutical manufacturer.

Average revenue per top 20 pharmaceutical manufacturer is calculated by taking the total revenue the company recognized through pharmaceutical

manufacturers listed in Fierce Pharma’s “The top 20 pharma companies by 2022 revenue” over the last twelve months, divided

by the total number of the aforementioned pharmaceutical manufacturers that our solutions helped support over that time period.

uses this metric to monitor its progress in “landing and expanding” with key customers within its largest customer vertical

and believes it also provides investors with a transparent way to chart our progress in penetrating this important customer segment.

decrease in the average in twelve months ended March 31, 2023 as compared to the twelve months ended March 31, 2022 is primarily

the result of the convergence of numerous macroeconomic factors that resulted in our customers slowing their rate of spend, particularly

for large and/or new implementations, which we believe prolonged sales cycles with the top 20 pharmaceutical manufacturers that were existing

Rolling Twelve Months

Ended March 31

Average revenue per top 20 pharmaceutical manufacturer

Percent of top 20 pharmaceutical manufacturers

that are customers.

Percent of top 20 pharmaceutical manufacturers that are customers is calculated by taking the number of revenue

generating customers that are pharmaceutical manufacturers listed in Fierce Pharma’s “The top 20 pharma companies by 2022

revenue” over the last 12 months, which is then divided by 20—which is the number of pharmaceutical manufacturers included

in the aforementioned list.

The Company uses this metric to monitor its progress in penetrating key customers within its largest customer

vertical and believes it also provides investors with a transparent way to chart our progress in penetrating this important customer segment.

Our penetration within this core customer group stayed consistent from the twelve months ended March 31, 2022 to the twelve months

ended March 31, 2023.

Rolling Twelve Months

Ended March 31

Percent of top 20 pharmaceutical manufacturers that are customers

Percent of total revenue attributable to top

20 pharmaceutical manufacturers.

Percent of total revenue attributable to top 20 pharmaceutical manufacturers is calculated by taking

the total revenue the company recognized through pharmaceutical manufacturers listed in Fierce Pharma’s “The top 20 pharma

companies by 2022 revenue” over the last twelve months, divided by our consolidated revenue over the same period.

The Company uses

this metric to monitor its progress in “landing and expanding” with key customers within its largest customer vertical and

believes it also provides investors with a transparent way to chart our progress in penetrating this important customer segment.

from customers that aren’t top 20 pharmaceutical manufacturers increased faster than our overall revenue, decreasing the percentage

of our overall revenues from top 20 pharmaceutical manufacturers.

Rolling Twelve Months

Ended March 31

Percent of total revenue attributable to top 20 pharmaceutical manufacturers

Net revenue retention.

Net revenue retention

is a comparison of revenue generated from all customers in the previous twelve-month period to total revenue generated from the same customers

in the following twelve-month period (i.e., excludes new customer relationships for the most recent twelve-month period).

uses this metric to monitor its ability to improve its penetration with existing customers and believes it also provides investors with

a metric to chart our ability to increase our year-over-year penetration and revenue with existing customers.

The retention rate in the

twelve months ended March 31, 2023 was lower due to the convergence of numerous macroeconomic factors that resulted in our customers

slowing their rate of spend, particularly for large and/or new implementations, which we believe prolonged sales cycles.

Rolling Twelve Months

Ended March 31

In addition, high levels of employee turnover across the pharmaceutical industry as well as a fewer number of U.S.

drug approvals could

create additional uncertainty within our target customer markets.

Historically, during periods of economic uncertainty and downturns,

businesses may slow spending, which may impact our business and our customers’ businesses.

Adverse changes in demand could impact

our business, collection of accounts receivable and our expected cash flow generation, which may adversely impact our financial condition

and results of operations.

Key Performance

monitor the following key performance indicators to help us evaluate our business, measure our performance, identify trends affecting

our business and make strategic decisions.

We have updated the definition of “top 20 pharmaceutical manufacturers” in our key

performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2022 revenue”.

We previously used “The top 20 pharma companies by 2020 revenue”.

As a result of this change, prior periods have been restated

for comparative purposes.

revenue per top 20 pharmaceutical manufacturer.

Average revenue per top 20 pharmaceutical manufacturer is calculated by taking the

total revenue the company recognized through pharmaceutical manufacturers listed in Fierce Pharma’s “The top 20 pharma companies

by 2022 revenue” over the last twelve months, divided by the total number of the aforementioned pharmaceutical manufacturers that

our solutions helped support over that time period.

The Company uses this metric to monitor its progress in “landing and expanding”

with key customers within its largest customer vertical and believes it also provides investors with a transparent way to chart our progress

in penetrating this important customer segment.

The decrease in the average in twelve months ended June 30, 2023 as compared to

the twelve months ended June 30, 2022 is primarily the result of the convergence of numerous macroeconomic factors that resulted

in our customers slowing their rate of spend, particularly for large and/or new implementations, which we believe prolonged sales cycles

with the top 20 pharmaceutical manufacturers that were existing customers.

Twelve Months

Ended June 30,

Average revenue per top 20 pharmaceutical

of top 20 pharmaceutical manufacturers that are customers.

Percent of top 20 pharmaceutical manufacturers that are customers is calculated

by taking the number of revenue generating customers that are pharmaceutical manufacturers listed in Fierce Pharma’s “The

top 20 pharma companies by 2022 revenue” over the last 12 months, which is then divided by 20—which is the number of pharmaceutical

manufacturers included in the aforementioned list.

The Company uses this metric to monitor its progress in penetrating key customers

within its largest customer vertical and believes it also provides investors with a transparent way to chart our progress in penetrating

this important customer segment.

Our penetration within this core customer group stayed consistent from the twelve months ended June 30,

2022 to the twelve months ended June 30, 2023.

Twelve Months

Ended June 30,

Percent of top 20 pharmaceutical

manufacturers that are customers

of total revenue attributable to top 20 pharmaceutical manufacturers.

Percent of total revenue attributable to top 20 pharmaceutical

manufacturers is calculated by taking the total revenue the company recognized through pharmaceutical manufacturers listed in Fierce

Pharma’s “The top 20 pharma companies by 2022 revenue” over the last twelve months, divided by our consolidated revenue

over the same period.

The Company uses this metric to monitor its progress in “landing and expanding” with key customers

within its largest customer vertical and believes it also provides investors with a transparent way to chart our progress in penetrating

this important customer segment.

Our revenue from customers that aren’t top 20 pharmaceutical manufacturers increased faster than

our overall revenue, decreasing the percentage of our overall revenues from top 20 pharmaceutical manufacturers.

Twelve Months

Ended June 30,

Percent of total revenue attributable

to top 20 pharmaceutical manufacturers

revenue retention.

Net revenue retention is a comparison of revenue generated from all customers in the previous twelve-month period

to total revenue generated from the same customers in the following twelve-month period (i.e., excludes new customer relationships for

the most recent twelve-month period).

The Company uses this metric to monitor its ability to improve its penetration with existing customers

and believes it also provides investors with a metric to chart our ability to increase our year-over-year penetration and revenue with

existing customers.

The retention rate in the twelve months ended June 30, 2023 was lower due to the convergence of numerous macroeconomic

factors that resulted in our customers slowing their rate of spend, particularly for large and/or new implementations, which we believe

prolonged sales cycles.

Twelve Months

Ended June 30,

Net revenue retention

Revenue per average full-time employee.

We define revenue per average full-time employee as total revenue over the last twelve months divided by the average number of employees

over the last twelve months (i.e., the average between the number of FTEs at the end of the reported period and the number of FTEs at

the end of the same period of the prior year).

The Company uses this metric to monitor the productivity of its workforce and its ability

to scale efficiently over time and believes the metric provides investors with a way to chart our productivity and scalability.

rate per employee declined year over year due to slower revenue growth and a higher average number of FTEs over the last 12 month period.

Rolling Twelve Months

Ended March 31

per average full-time employee.

We define revenue per average full-time employee as total revenue over the last twelve months divided

by the average number of employees over the last twelve months (i.e., the average between the number of FTEs at the end of the reported

period and the number of FTEs at the end of the same period of the prior year).

The Company uses this metric to monitor the productivity

of its workforce and its ability to scale efficiently over time and believes the metric provides investors with a way to chart our productivity

and scalability.

Our revenue rate per employee declined year over year due to slower revenue growth and a higher average number of FTEs

over the last 12 month period.

Twelve Months

Ended June 30,

Revenue per average full-time employee

Results of Operations for the Three Months Ended March 31,

2023 and 2022

The following table sets forth, for the periods

indicated, the dollar value and percentage of net revenue represented by certain items in our consolidated statements of operations:

Three months ended March 31,

(in thousands, except percentage data)

of Operations for the Three and Six Months Ended June 30, 2023 and 2022

following tables sets forth, for the periods indicated, the dollar value and percentage of net revenue represented by certain items in

our consolidated statements of operations:

months ended June 30,

Cost of revenues

5 unchanged sentences

$ (3,884,714 )

* Balances and percentage of net revenue information may not

add due to rounding

Our net revenue reported for the three months

ended March 31, 2023 was approximately $13.0 million, a decrease of 5% over the approximately $13.7 million from the same period

The decrease in revenue was primarily driven by the macroeconomic pressures affecting our customers.

and percentage of net revenue information may not add due to rounding

months ended June 30,

Cost of revenues

Our cost of revenues, composed primarily of revenue

share expense paid to our network partners, remained relatively consistent at $5.6 million for the three months ended March 31, 2023

compared to the same period of 2022.

Our cost of revenues as a percentage of revenue increased to approximately 42.8% for the quarter

ended March 31, 2023 from approximately 41.0% for the quarter ended March 31, 2022.

This increase in cost of revenue as a percentage

of revenue was a result of solution and channel mix.

Additional discussion is included in the gross margin section below.

Our gross margin, which is the difference between

our revenues and our cost of revenues, decreased for the three months ended March 31, 2023, as a result of solution and channel mix.

During the three months ended March 31, 2023, there was a decrease in the percentage of activity flowing through our lower cost channels

compared with a year ago.

Operating expenses

Operating expenses increased to approximately

$14.5 million for the three months ended March 31, 2023 from approximately $11.9 million for the same period in 2022, an increase of approximately

The detail by major category is reflected in the table below.

Three Months Ended

Loss from operations

(11,945,054 )

Loss before provision for income taxes

(10,559,163 )

Income tax benefit

$ (10,559,163 )

$ (7,645,812 )

and percentage of net revenue information may not add due to rounding

Our net revenue reported for the three months ended June 30, 2023

was approximately $13.8 million, a decrease of 1% over the approximately $14.0 million from the same period in 2022.

Our net revenue reported

for the six months ended June 30, 2023 was approximately $26.8 million, a decrease of 3% over the approximately $27.7 million from

the same period in 2022.

The decrease in revenue was primarily as a result of a revenue shortfall in certain non-core business lines as

well as longer than expected medical, legal and regulatory reviews that pushed revenue into the second half of the year.

revenue continues to be effected by the macroeconomic pressures affecting our customers.

cost of revenues, composed primarily of revenue share expense paid to our network partners, was approximately $6.0 million for the three

months ended June 30, 2023 compared to $5.0 million for the same period of 2022.

Our cost of revenues for the six month period ended

June 30, 2023 increased from $10.6 million to $11.6 million, compared to the same period in 2022.

Our cost of revenues as a percentage

of revenue increased to approximately 43.4% for the quarter ended June 30, 2023 from approximately 35.7% for the quarter ended June 30,

Our cost of revenues as a percentage of revenue increased to approximately 43.1% for the six months ended June 30, 2023 from

approximately 38.3% for the six months ended June 30, 2022.

This increase in cost of revenue as a percentage of revenue was a result

of solution and channel mix.

Additional discussion is included in the gross margin section below.

gross margin, which is the difference between our revenues and our cost of revenues, decreased for the three and six months ended June 30,

2023, as a result of solution and channel mix.

During the six months ended June 30, 2023, there was a decrease in the percentage

of activity flowing through our lower cost channels compared with a year ago.

expenses decreased to approximately $12.7 million for the three months ended June 30, 2023 from approximately $12.9 million for

the same period in 2022, a decrease of approximately 1%.

Operating expenses increased from approximately $24.8 million for the six months

ended June 30, 2022 to approximately $27.2 million for the same period in 2023, an increase of approximately 10%.

The detail by major

category is reflected in the table below.

Stock-based compensation

Depreciation, amortization and noncash lease expense

Other general and administrative expenses

Depreciation, amortization and noncash lease

Other general and administrative

Total operating expense

The greatest increase was in stock-based compensation,

a non-cash expense.

Stock-based compensation is awarded to all full-time employees upon their start of employment as well as to directors,

officers and certain key employees to provide an equity-based incentive to maintain and enhance the performance and profitability of the

Other general and administrative expenses increased by $1.4 million over the same period prior year, mostly as a result of an

increase in headcount as well as other investments to support our growth initiatives and operations.

We had a net loss of approximately $6.4 million

for the three months ended March 31, 2023, as compared to a net loss of approximately $3.8 million during the same period in 2022.

The reasons and specific components associated with the change are discussed above.

Liquidity and Capital Resources

Historically, our primary sources of liquidity

have been cash receipts from customers and proceeds from equity offerings.

As of March 31, 2023, we had total current assets of

approximately $95.9 million, compared with current liabilities of approximately $7.6 million, resulting in working capital of approximately

$88.3 million and a current ratio of approximately 13 to 1 at March 31, 2023.

This decrease in our working capital, as discussed in more

detail below, is primarily the result of the timing of prepaid services and investment in our reporting infrastructure.

Following is a table with summary data from the

consolidated statements of cash flows for the three months ended March 31, 2023 and 2022, as presented.

Three Months Ended

Net cash (used in) / provided by operating activities

Net cash used in investing activities

Net cash (used in) / provided by financing activities

Net (decrease) / increase in cash and cash equivalents

We used approximately $0.1 million for operating

activities during the three months ended March 31, 2023, compared with $4.1 million provided by operating activities in the same

period in 2022.

We had a net loss of $6.4 million for the first quarter of 2023, but noncash expenses of $5.0 million and working capital

generated by the collection of receivables offset the loss.

Additionally, there were differences in the timing of prepaid services that

affected the first quarter change in working capital year over year.

Cash used in investing activities was approximately

$1.5 million for the three months ended March 31, 2023.

We purchased $56.9 million in treasury bills with maturity dates in 2023.

This allowed the Company to earn a higher rate of interest on excess cash for the period.

These purchases were partially offset by the

redemption of $55.6 million in treasury bills.

Cash used for financing activities was approximately

$0.1 million related to the payment of withholding taxes on behalf of the employees for the vesting of restricted stock units during the

three months ended March 31, 2023.

This value represents the stock units surrendered and cancelled.

This cost was partially offset

by proceeds received as a result of option exercises during the period.

We had proceeds from financing activities of approximately $0.3

million related to the exercise of stock options during the three months ended March 31, 2022.

We believe that funds generated from operations,

together with existing cash, will be sufficient to finance our current operations and planned growth for the next twelve (12) months.

greatest increase was in other general and administrative expenses.

Other general and administrative expenses increased from approximately

$8.3 million for the three months ended June 30, 2022 to approximately $8.7 million for the same period in 2023.

Other general and administrative

expenses increased from $16.5 million for the six months ended June 30, 2022 to approximately $18.4 million for the same period in 2022.

This increase is mostly as a result of an increase in headcount as well as other investments to

support our growth initiatives and operations.

had a net loss of approximately $4.2 million for the three months ended June 30, 2023, as compared to a net loss of approximately

$3.9 million during the same period in 2022.

We had a net loss of approximately $10.6 million for the six months ended June 30,

2023, as compared to a net loss of approximately $7.6 million during the same period in 2022.

The reasons and specific components associated

with the change are discussed above.

and Capital Resources

Historically,

our primary sources of liquidity have been cash receipts from customers and proceeds from equity offerings.

As of June 30, 2023,

we had total current assets of approximately $85.1 million, compared with current liabilities of approximately $5.5 million, resulting

in working capital of approximately $79.6 million and a current ratio of approximately 15.4 to 1.

This represents a decrease from our

working capital of approximately $90.2 million and an increase from the current ratio of 11.7 to 1 at December 31, 2022.

This decrease

in our working capital is discussed in more detail below.

is a table with summary data from the consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, as

Net cash (used in) / provided by

operating activities

$ (2,454,489 )

Net cash provided by / (used in) investing

Net cash (used in) /

provided by financing activities

Net (decrease) / increase

in cash and cash equivalents

$ (8,400,355 )

used approximately $2.5 million for operating activities during the six months ended June 30, 2023, compared with $4.4 million provided

by operating activities in the same period in 2022.

We had a net loss of $10.6 million for the first six months of 2023.

Noncash expenses

of $9.1 million and working capital generated by the collection of receivables partially offset the loss.

Additional channel partner

investment in the second quarter of 2023 as well as the timing of certain revenue share payments increased our balance of prepaid services

year over year.

This in conjunction with the greater net loss, led to the year over year decrease cash flow from operations.

provided by investing activities was approximately $1.7 million for the six months ended June 30, 2023.

We redeemed $112.5 million

in treasury bills which was partially offset by reinvestment of $109.5 million in treasury bills.

We also invested in internally developed

software in the amount of $1.3 million.

used for financing activities was approximately $7.6 million mostly related to a company stock repurchase program approved in March 2023.

During the quarter ended June 30, 2023 we used $7.5 million to purchase 526,999 shares of common stock.

Additionally, we used $0.2 million

to pay withholding taxes on behalf of employees vesting in restricted stock units.

This activity was partially offset by the receipt

of funds from the exercise of stock options.

believe that funds generated from operations, together with existing cash, will be sufficient to finance our current operations for the

next twelve (12) months.

In addition, we believe we can generate the cash needed to operate beyond the next 12 months from operations.

However, we may seek additional

debt or equity financing to supplement cash from operations to fund acquisitions or strategic partner relationships, make capital expenditures,

and satisfy working capital needs.

Critical Accounting Estimates

We prepare our consolidated financial statements

in conformity with accounting principles generally accepted in the United States.

The preparation of these financial statements requires

the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial

statements and reported amounts of revenues and expenses during the periods presented.

Actual results could differ from those estimates

and assumptions.

Our significant accounting policies are described in Note 2 to the Consolidated Financial Statements in the Annual Report

on Form 10-K for the year ended December 31, 2022 (2022 Annual Report on Form 10-K).

The accounting policies we used in preparing

these financial statements are substantially consistent with those we applied in our 2022 Annual Report on Form 10-K.

Our critical accounting

estimates are described in Management’s Discussion and Analysis included in the 2022 Annual Report on Form 10-K.

Recently Issued Accounting Pronouncements

ASU Topic 2021-08 Business Combinations (Topic

805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , requires contract assets and contract

liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with

ASC 606 , Revenue from Contracts with Customers , as if it had originated the contracts.

The standard was effective for the Company’s

fiscal year beginning January 1, 2023.

The adoption of this standard did not have a material effect on our financial position, results

of operations, or cash flows.

Off Balance Sheet Arrangements

The Company has contracts with various electronic health records systems

and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons or banners through their network.

From time to time the Company enters into arrangements with a partner to acquire minimum amounts of messaging capabilities.

31, 2023, the Company had commitments for future minimum payments of $14.9 million that will be reflected in cost of revenues during the

years 2023 through 2025.

However, we may seek additional debt, equity financing, or lines of credit to supplement cash from operations to fund acquisitions or

strategic partner relationships, make capital expenditures, and satisfy working capital needs.

Accounting Estimates

prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States.

The preparation

of these financial statements requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and

liabilities at the date of the financial statements and reported amounts of revenues and expenses during the periods presented.

results could differ from those estimates and assumptions.

Our significant accounting policies are described in Note 2 to the Consolidated

Financial Statements in the Annual Report on Form 10-K for the year ended December 31, 2022 (2022 Annual Report on Form 10-K).

accounting policies we used in preparing these financial statements are substantially consistent with those we applied in our 2022 Annual

Report on Form 10-K.

Our critical accounting estimates are described in Management’s Discussion and Analysis included in the 2022

Annual Report on Form 10-K.

Issued Accounting Pronouncements

Topic 2021-08 Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ,

requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on

the acquisition date in accordance with ASC 606 , Revenue from Contracts with Customers , as if it had originated the contracts.

The standard was effective for the Company’s fiscal year beginning January 1, 2023.

The adoption of this standard did not have

a material effect on our financial position, results of operations, or cash flows.

Sheet Arrangements

Company has contracts with various electronic health records systems and ePrescribe platforms, whereby we agree to share a portion of

the revenue we generate for eCoupons or banners through their network.

From time to time the Company enters into arrangements with a

partner to acquire minimum amounts of messaging capabilities.

As of June 30, 2023, the Company had commitments for future minimum payments

of $13.3 million that will be reflected in cost of revenues during the years 2023 through 2025.

Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis